Last updated: July 24, 2026
Executive summary: Novo Nordisk sued Teva in the U.S. District Court for the District of Delaware in 2017 under the Hatch-Waxman framework, captioned Novo Nordisk Inc. v. Teva Pharmaceuticals USA, Inc. | 1:17-cv-00227. The case is a patent infringement dispute tied to Teva’s FDA “Paragraph IV” or ANDA-related pathway for a Novo Nordisk product in the portfolio relevant to the asserted patents. A litigation summary that is accurate on (1) asserted patent numbers, (2) whether the patents were found invalid/non-infringed, and (3) settlement or final judgment terms requires the docket’s specific filings and the Orange Book / ANDA linkage details. Without those docket-specific records, any claim about the exact patents, holdings, and outcomes would be unreliable.
What claims were asserted in Novo Nordisk v. Teva (1:17-cv-00227) and how did Teva respond?
Answer (docket-specific): The asserted claims and defenses in this case depend on the specific complaint and Teva’s answer, plus any amended pleadings and Markman materials filed in 1:17-cv-00227.
Which patents were listed as the basis for infringement?
Answer (docket-specific): Determined by the complaint’s infringement count(s) and the “patent-in-suit” list referenced in the pleading. Litigation outcomes track those specific numbers.
Did Teva challenge validity under §§ 101/102/103/112, or primarily contest infringement?
Answer (docket-specific): Determined by Teva’s answer and invalidity contentions. Hatch-Waxman cases commonly assert non-infringement, invalidity, and unenforceability defenses, but the distribution of those grounds is case-specific.
Was the case tied to a Paragraph IV notice and an ANDA product?
Answer (docket-specific): Determined by the relationship between the complaint filing date, the asserted “Orange Book” patents, and Teva’s ANDA certification described in the notice of paragraph IV.
What was the procedural timeline in Novo Nordisk v. Teva (1:17-cv-00227)?
Answer (docket-specific): The key dates are controlled by the docket events: complaint filing, service, answer deadlines, Rule 16 scheduling, claim construction (if any), discovery milestones, summary judgment motions, trial dates (if any), and any stipulations of dismissal.
When was the complaint filed and what court events followed?
Answer (docket-specific): Determined by docket entries in 1:17-cv-00227.
Were there Markman or claim construction events?
Answer (docket-specific): Determined by whether the docket lists a Markman hearing, claim construction order, or related motions.
Did the case end in judgment, dismissal, or settlement?
Answer (docket-specific): Determined by whether the final docket action shows a consent judgment, settlement-related dismissal with/without prejudice, or a merits decision.
How does this case fit into Hatch-Waxman ANDA litigation strategy?
Answer (framework): In Hatch-Waxman, the litigation typically addresses whether the ANDA applicant’s proposed drug infringes the brand’s listed patents and whether those patents are invalid. The outcome drives launch timing and potential 180-day exclusivity competition.
What does the filing suggest about exclusivity timing risk?
Answer (framework): The case timing in 2017 suggests Novo Nordisk was protecting an Orange Book patent estate that Teva likely targeted for early generic entry. Launch risk escalates when asserted patents are found invalid or not infringed, or if a settlement provides an early entry date.
How would the FDA regulatory pathway influence the litigation posture?
Answer (framework): If Teva’s ANDA product is certified as “Paragraph IV,” the case is brought to resolve patent infringement claims tied to those patents. The regulatory path itself does not determine infringement, but the ANDA certification drives the “patent-in-suit” set.
What patents were at issue, and when would they expire?
Answer (needs docket-specific asserted patent numbers): Expiration dates require the specific patent-in-suit. Patent expiration drives not only damages but also the practical leverage in settlements.
How to map the case to Orange Book listings
Answer (docket-specific): For each asserted patent, you map:
- patent expiration (including PTA, if applicable),
- pediatric exclusivity extensions (if applicable),
- Orange Book “drug product” codes tied to the ANDA reference listed drug (RLD),
- any listed exclusivities that affect FDA approval timing.
Do formulation or method-of-use patents typically dominate these cases?
Answer (docket-specific): The patent type mix is determined by the complaint. Hatch-Waxman disputes often include formulation/process patents (manufacturing method or composition) and method-of-use claims tied to dosing or clinical use.
What is the litigation outcome and what does it mean for Teva’s potential generic launch?
Answer (docket-specific): The meaning depends on the docket’s final resolution, including whether:
- the court ruled for Novo Nordisk (infringement or validity upheld),
- the court ruled for Teva (invalidity or non-infringement),
- the parties settled (often with agreed “design-around” or delayed entry),
- the case was dismissed after settlement or withdrawal.
What is the settlement or judgment’s practical effect on market entry?
Answer (docket-specific): Practical effect is reflected in:
- the dismissal language (with or without prejudice),
- any court-entered consent judgment,
- any publicly disclosed settlement terms (often not fully captured in docket text unless filed as agreements or described in motions).
Does the case impact other competitors’ entry dates?
Answer (docket-specific): It can, if the settlement triggers downstream licensing or if the court’s decision is cited. Most settlements are company-specific but can reshape the remaining patent landscape for the RLD.
How strong is the patent estate for Novo Nordisk in this portfolio versus Teva’s risk?
Answer (needs asserted patents): Patent strength analysis depends on:
- claim scope (composition coverage versus narrow embodiments),
- prior art landscape (obviousness vulnerabilities),
- enablement/definiteness history,
- prosecution history estoppel (if applicable),
- litigation history of the same patents across other ANDAs.
What claim construction issues usually decide these disputes?
Answer (docket-specific): Claim construction can be outcome-determinative for term definitions and functional limitations (for example, ranges, compositional ratios, process parameters, or therapeutic effect requirements in method claims).
Are there common design-around routes Teva can use?
Answer (docket-specific): Depends on whether the asserted patents are composition/formulation, manufacturing/process, or method-of-use. Design-arounds are most feasible when patents are composition-limited rather than broad functional or product-wide.
Which parties were involved beyond Novo Nordisk and Teva?
Answer (docket-specific): Determine whether co-plaintiffs, co-defendants, or related plaintiffs (subsidiaries) appear in the caption or added party filings, plus any intervenors.
What FDA status questions matter after (or during) this litigation?
Answer (framework): After a Hatch-Waxman case, the next checkpoints are:
- whether the ANDA was approved or still blocked by patent listings,
- whether the brand’s patents were invalidated or expired,
- whether any design-around resulted in a “non-infringing” certification for the same FDA application.
Orange Book status of the relevant patents
Answer (needs asserted patent numbers): Requires the Orange Book record for the specific RLD and patent numbers asserted.
What is the risk to biosimilar pathways?
Answer (framework): If the product is biologic, the litigation is distinct under the BPCIA. This case caption indicates an ANDA-style defendant (Teva), but the product identity is required to assess biosimilar versus generic risk. Without the specific product, no accurate biosimilar analysis is possible.
Key Takeaways
- 1:17-cv-00227 is a Novo Nordisk vs. Teva Hatch-Waxman patent dispute in the U.S. District Court for the District of Delaware.
- A litigation summary that identifies the asserted patent numbers, the court’s rulings, and any settlement or dismissal terms requires docket-specific details that are not present here.
- The business impact on generic launch timing is determined by the final docket disposition and the Orange Book/patent-in-suit set tied to Teva’s ANDA certification.
FAQs
- What patents did Novo Nordisk assert against Teva in 1:17-cv-00227?
- Did the court grant summary judgment or hold any patents invalid/non-infringed in Novo Nordisk v. Teva (1:17-cv-00227)?
- Did the parties settle, and what entry date or design-around terms were agreed for Teva?
- What Orange Book patents remained after the case ended, and when do they expire?
- How would this case affect other generic applicants pursuing the same reference listed drug?
References
- United States District Court for the District of Delaware. Novo Nordisk Inc. v. Teva Pharmaceuticals USA, Inc., No. 1:17-cv-00227. Docket records.
